Lead future growth and transformation for biopharma with general management P&L responsibility for 170+ employees encompassing R&D, clinical manufacturing, clinical development, pharmacovigilance, global medical affairs, M&A/corporate partnering, and corporate strategy. Chair of Product Development and M&A Committees.

Direct report to CEO work closely with CEO, CFO and Board of Directors to develop and execute forward thinking strategy for the enterprise. Lead Business Development & Licensing, Corporate Strategy, Portfolio Management and Enterprise Governance.

Direct report to CEO. Established and lead Transformation Office ensuring organizational execution on key strategic imperatives.

Lead Corporate Strategy Development and Strategy Realization to include corporate development, governance and product portfolio management. Partner with Executive Team to identify and provide guidance on business priorities.

A member of the Senior Leadership Team responsible for defining strategy and operational engagement with International customers. Accountable to Chief Council, EVP Strategy and EVP Business Operations.Specific areas of focus include:• Strategic Execution: Drive visibility and alignment across the company that fosters accountability and quality decision-making to achieve International MCM strategic objectives.• Enterprise Operations: Prioritize and align cross-functional operating policies and processes to ensure International MCM strategy is accurately translated into successful execution.• Change Enablement: Foster change agility and employee resiliency to increase benefit realization of Emergent’s International MCM strategy while minimizing business disruption.

A member of the Senior Leadership Team responsible for leading and building global commercial capabilities to support Emergent's diverse portfolio. Key areas of focus include: New Product Planning & Commercial Assessment, (Marketing) Portfolio Strategy, International Account Management, Global Pricing, Contracting & Channel Strategy delivery, Commercial Training, Commercial Insight, Sales and Marketing Operations.

The healthcare industry and each of us as potential patients, depend on scientific advancements to prevent, treat or even cure our ailments. The drug development industry partnered with the top global scientific minds strives to do just that. But what happens after the science becomes a drug? Commercialization for the Biopharmaceutical Industry is an introductory graduate level course in the commercialization of complex biologics/specialty drugs . This course covers primarily the US market with some emphasis on the growing opportunities and challenges of emerging markets.

A thought partner leading engagements of both strategic and operational nature for the healthcare industry. Recent engagements include: Strategic Advisor to C-suite, Portfolio Strategy, Asset Valuation, Commercial Capability builds, Global Public Health- New business ventures, Global Marketing

Responsible for ~$250M Chemical Medicines (small molecule) P&L. Leading the continued development of USP’s global strategy in the Chemical Medicines/small molecules space, and overseeing the flawless execution of USP’s strategy for Chemical Medicines globally. Focused on growth strategies for legacy products/services as well as diversification through new business models for key global geographies.

Division Vice President leading Commercial Training & Development, Sales & Marketing Operations, Marketing Sciences (in-line brands)/Commercial Insight/New Product Planning (pipeline assets), Commercial Innovation and Commercial IS in support of $1.5BN franchise and extensive product development portfolio.

Department Head for Commercial Business Operations; includes Strategic Pricing & Contracting, Contract Operations & Channel Strategy.

Established, launched and managed enterprise PMO, strengthening prioritization, delivery and termination of $4B product pipeline. Setup R&D governance structure as key player in integration of $1.3B global acquisition.Facilitated post-acquisition investment decisions as well as asset valuation, determining resource requirements and allocation following $15B acquisition by Fortune 500 leader.Partnered to develop Emerging Markets/New Product Planning capabilities for extensive biologics portfolioProduct Development Team Lead focused in Respiratory Disease and Infectious Disease

Managed team of 6 Project Management professionals, Global Program Director for multi-national development program- phase 1-3 including FDA submission and post-approval requirements- for large pharmaceutical partner.